# A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

> **NCT04999605** · PHASE1,PHASE2 · TERMINATED · sponsor: **Akeso** · enrollment: 8 (actual)

## Conditions studied

- Ovarian Neoplasms
- Recurrent Ovarian Carcinoma
- Relapsed Ovarian Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** AK112 low dose
- **DRUG:** AK112 medium dose
- **DRUG:** AK112 high dose

## Key facts

- **NCT ID:** NCT04999605
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-24
- **Primary completion:** 2022-06-10
- **Final completion:** 2022-06-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Too low inclusion rate
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04999605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04999605, "A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT04999605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*